{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:15Z","timestamp":1740144015185,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40256-024-00690-0","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:11:55Z","timestamp":1730193115000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Antibacterials on the Quality of Anticoagulation Control in Patients Initiating Warfarin Therapy"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-2316","authenticated-orcid":false,"given":"Kyohei","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3508","authenticated-orcid":false,"given":"Keita","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"690_CR1","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1253\/circj.CJ-20-0135","volume":"84","author":"C Izumi","year":"2020","unstructured":"Izumi C, Eishi K, Ashihara K, Arita T, Otsuji Y, Kunihara T, et al. JCS\/JSCS\/JATS\/JSVS 2020 guidelines on the management of valvular heart disease. Circ J. 2020;84:2037\u2013119. https:\/\/doi.org\/10.1253\/circj.CJ-20-0135.","journal-title":"Circ J"},{"key":"690_CR2","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2017-09-804666","volume":"131","author":"MA Rishavy","year":"2018","unstructured":"Rishavy MA, Hallgren KW, Wilson L, Singh S, Runge KW, Berkner KL. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. Blood. 2018;131:2826\u201335. https:\/\/doi.org\/10.1182\/blood-2017-09-804666.","journal-title":"Blood"},{"issue":"3","key":"690_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/08998280.2001.11927781","volume":"14","author":"M Kuruvilla","year":"2001","unstructured":"Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc (Bayl Univ Med Cent). 2001;14(3):305\u20136. https:\/\/doi.org\/10.1080\/08998280.2001.11927781.","journal-title":"Proc (Bayl Univ Med Cent)."},{"key":"690_CR4","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1111\/bcp.14833","volume":"87","author":"M Wang","year":"2021","unstructured":"Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L, et al. Drug\u2013drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87:4051\u2013100. https:\/\/doi.org\/10.1111\/bcp.14833.","journal-title":"Br J Clin Pharmacol"},{"key":"690_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.829304","volume":"9","author":"H Yan","year":"2022","unstructured":"Yan H, Chen Y, Zhu H, Huang WH, Cai XH, Li D, et al. The relationship among intestinal bacteria, vitamin K and response of vitamin K antagonist: a review of evidence and potential mechanism. Front Med (Lausanne). 2022;9: 829304. https:\/\/doi.org\/10.3389\/fmed.2022.829304.","journal-title":"Front Med (Lausanne)."},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40560-020-00517-5","volume":"9","author":"S Dahlberg","year":"2021","unstructured":"Dahlberg S, Sch\u00f6tt U, Kander T. The effect of vitamin K on prothrombin time in critically ill patients: an observational registry study. J Intensive Care. 2021;9:1\u20139. https:\/\/doi.org\/10.1186\/s40560-020-00517-5.","journal-title":"J Intensive Care"},{"key":"690_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164076","volume":"28","author":"S Haas","year":"2016","unstructured":"Haas S, Ten CH, Accetta G, Angchaisuksiri P, Bassand JP, John Camm A, et al. Quality of vitamin k antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS ONE. 2016;28: e0164076. https:\/\/doi.org\/10.1371\/journal.pone.0164076.","journal-title":"PLoS ONE"},{"key":"690_CR8","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIR.0000000000000932","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Rwin JP, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35-71. https:\/\/doi.org\/10.1161\/CIR.0000000000000932.","journal-title":"Circulation"},{"key":"690_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1253\/circj.66.668","volume":"66","author":"K Matsuyama","year":"2002","unstructured":"Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Yoshida K, Tokuda Y, et al. Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J. 2002;66:668\u201370. https:\/\/doi.org\/10.1253\/circj.66.668.","journal-title":"Circ J"},{"key":"690_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1253\/circj.CJ-14-1057","volume":"79","author":"E Kodani","year":"2015","unstructured":"Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T. Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation: Subanalysis of the J-RHYTHM registry. Circ J. 2015;79:325\u201330. https:\/\/doi.org\/10.1253\/circj.CJ-14-1057.","journal-title":"Circ J"},{"key":"690_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/joa3.12714","volume":"38","author":"K Ono","year":"2022","unstructured":"Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, et al. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. J Arrhythmia. 2022;38:833\u2013973. https:\/\/doi.org\/10.1002\/joa3.12714.","journal-title":"J Arrhythmia."},{"key":"690_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, Van Der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236\u20139.","journal-title":"Thromb Haemost"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","volume":"107","author":"J Hirsh","year":"2003","unstructured":"Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association\/American College of Cardiology foundation guide to warfarin therapy. Circulation. 2003;107:1692\u2013711. https:\/\/doi.org\/10.1161\/01.CIR.0000063575.17904.4E.","journal-title":"Circulation"},{"key":"690_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188482","volume":"20","author":"AS Vestergaard","year":"2017","unstructured":"Vestergaard AS, Skj\u00f8th F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS ONE. 2017;20: e0188482. https:\/\/doi.org\/10.1371\/journal.pone.0188482.","journal-title":"PLoS ONE"},{"key":"690_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/RMHP.S248222","volume":"13","author":"S Alghadeeer","year":"2020","unstructured":"Alghadeeer S, Alzahrani AA, Alalayet WY, Alkharashi AA, Alarifi MN. Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: a prospective observational study. Risk Manag Healthc Policy. 2020;13:1175\u20139. https:\/\/doi.org\/10.2147\/RMHP.S248222.","journal-title":"Risk Manag Healthc Policy."},{"key":"690_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm12123887","volume":"12","author":"A Alshaiban","year":"2023","unstructured":"Alshaiban A, Alavudeen SS, Alshahrani I, Kardam AM, Alhasan IM, Alasiri SA, et al. Impact of clinical pharmacist running anticoagulation clinic in Saudi Arabia. J Clin Med. 2023;12:1\u201315. https:\/\/doi.org\/10.3390\/jcm12123887.","journal-title":"J Clin Med"},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.thromres.2009.11.032","volume":"126","author":"V Giuliano","year":"2010","unstructured":"Giuliano V, Bassotti G, Mourvaki E, Castellani D, Filippucci E, Sabatino G, et al. Small intestinal bacterial overgrowth and warfarin dose requirement variability. Thromb Res. 2010;126:12\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2009.11.032.","journal-title":"Thromb Res"},{"key":"690_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1060028020940728","volume":"55","author":"T Yagi","year":"2021","unstructured":"Yagi T, Naito T, Kato A, Hirao K, Kawakami J. Association between the prothrombin time-international normalized ratio and concomitant use of antibiotics in warfarin users: focus on type of antibiotic and susceptibility of Bacteroides fragilis to antibiotics. Ann Pharmacother. 2021;55:157\u201364. https:\/\/doi.org\/10.1177\/1060028020940728.","journal-title":"Ann Pharmacother"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00690-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00690-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00690-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:28:21Z","timestamp":1739172501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00690-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00690-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"3 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kyohei Sugiyama, Keita Hirai, Masato Tsutsumi, Shota Furuya, and Kunihiko Itoh declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This study was conducted with the approval of the ethics committee of Shizuoka General Hospital (approved number: SGHIRB#2021077).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.S. and K.H. designed the study. K.S., M.T., S.F. and K.I. performed the experiments. K.S. and K.H. analyzed the data. K.S. and K.H. wrote the manuscript. All the authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}